Arcutis Biotherapeutics
Logotype for Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics (ARQT) investor relations material

Arcutis Biotherapeutics TD Cowen 46th Annual Health Care Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Arcutis Biotherapeutics Inc
TD Cowen 46th Annual Health Care Conference summary2 Mar, 2026

Financial performance and growth

  • Achieved $127.5 million in Q4 net revenue, exceeding consensus by $15 million, and $372 million for the year, with TRX doubling year-over-year.

  • Portfolio-wide growth in Q4, with 19% demand growth and gross-to-net maintained in the 50s; expecting typical seasonality in Q1 2026.

  • Cash flow breakeven reached last quarter, with commitment to maintain positive cash flow and operating leverage as top-line grows faster than expenses.

  • Profitable in Q3 and Q4, with profits expected to fluctuate due to non-cash items, but cash management remains a priority.

Commercial strategy and market expansion

  • Holds nearly 50% of the branded nonsteroidal topical market, with strong execution and additional product approvals in 2025.

  • Dermatology sales force expanding by 30 representatives to 160, targeting mid-decile prescribers for broader reach.

  • Building a dedicated primary care and pediatric sales force, starting with a pilot of 30, aiming for impact in the back half of the year.

  • Partnership with PGA golfer Max Homa to raise awareness for seborrheic dermatitis and ZORYVE.

  • Medicare formulary win gives access to one-third of Medicare lives, with plans to expand further in 2026-2027.

Product pipeline and R&D updates

  • NDA filing for ZORYVE in infants (3-24 months) planned for Q2, with anticipated approval for plaque psoriasis in ages 2-5 by end of June.

  • Ongoing Phase II trials in hidradenitis suppurativa (HS) and vitiligo, with promising early case reports; POC studies to guide further development.

  • ARQ-234, a novel atopic dermatitis treatment, entering the clinic this quarter, targeting immune checkpoint agonism for potential disease remission.

  • Additional POC studies in other indications planned for 2024, with prioritization based on clinical promise.

Steroid conversion: key tactics for acceleration?
Prioritize pipeline assets for value creation.
What drives sustained cash flow positivity?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Arcutis Biotherapeutics earnings date

Logotype for Arcutis Biotherapeutics Inc
Q1 20265 May, 2026
Arcutis Biotherapeutics
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Arcutis Biotherapeutics earnings date

Logotype for Arcutis Biotherapeutics Inc
Q1 20265 May, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Arcutis Biotherapeutics Inc. is a biopharmaceutical company focused on developing treatments for immune-mediated dermatological conditions. The company aims to address unmet needs in the dermatology field by creating therapies that offer improved safety and efficacy profiles for patients. Arcutis Biotherapeutics develops topical treatments for a range of skin conditions, leveraging its expertise in immunology and drug delivery to target diseases affecting the skin, hair, and nails. Its pipeline includes therapies designed to manage chronic inflammatory skin diseases. The company is headquartered in Westlake Village, California, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage